SCHEMBL19965701

SCHEMBL19965701

CCCCC(CC)C(=O)Nc1cc(C)no1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.52
ALDH1A1 P00352 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
TSHR P16473 1/20 0.48
MEN1 O00255 1/20 0.48
MAPT P10636 1/20 0.48
MAPK1 P28482 1/20 0.48
KMT2A Q03164 1/20 0.48
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
CA7 P43166 1/20 0.46
CA14 Q9ULX7 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
ADORA2B P29275 1/20 0.44
POLB P06746 2/20 0.44
MLYCD O95822 1/20 0.43
GLA P06280 1/20 0.42
PKM P14618 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19197577 0.90 ALDH1A1 (0.50) LMNAALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL19232076 0.80 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2TSHRCA1ADORA2B
SCHEMBL19965633 0.78 ALDH1A1 (0.58) LMNAALDH1A1SMN1; SMN2ADORA2BPOLB
SCHEMBL11594452 0.77 CA2 (0.48) LMNAALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL12245070 0.76 LMNA (0.67) LMNAALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL15000477 0.74 ALDH1A1 (0.60) LMNAALDH1A1SMN1; SMN2KMT2AADORA2B
SCHEMBL11596591 0.73 CA1 (0.44) LMNAALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL11832069 0.72 CA2 (0.59) LMNAALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL17833337 0.72 ALDH1A1 (0.73) LMNAALDH1A1SMN1; SMN2TSHRKMT2A
SCHEMBL1896996 0.71 ALDH1A1 (0.66) ALDH1A1SMN1; SMN2MEN1KMT2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10695328-B2 Aryl dihydropyridinones and piperidinone MGAT2 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2020-06-30 US disclosed
US-20190314346-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-10-17 US disclosed
US-10399933-B2 Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer BRISTOL-MYERS SQUIBB COMPANY (US) 2019-09-03 US disclosed
US-20180072660-A1 INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER BRISTOL MYERS SQUIBB CO (US) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190314346-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS DGAT2, MGAT2, MGAT1 LMNA 4292/4885ALDH1A1 284/4885SMN1; SMN2 4109/4885
US-20180072660-A1 INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER IDO1, IDO2, INMT LMNA 4373/4885ALDH1A1 263/4885SMN1; SMN2 4521/4885
US-10695328-B2 Aryl dihydropyridinones and piperidinone MGAT2 inhibitors DGAT2, MGAT2, MGAT1 LMNA 4292/4885ALDH1A1 284/4885SMN1; SMN2 4109/4885
US-10399933-B2 Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer IDO1, IDO2, INMT LMNA 4373/4885ALDH1A1 263/4885SMN1; SMN2 4521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.